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Effects of Roux-en-Y gastric bypass on fasting and
postprandial inflammation-related parameters in
obese subjects with normal glucose tolerance
and in obese subjects with type 2 diabetes
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Abstract
Background: Obesity is characterized by low grade inflammation and an altered secretion of inflammatory
cytokines from the adipose tissue. Weight loss has shown to reduce inflammation; however, changes in cytokine
profiles during massive weight loss are not well described. The present study explored the hypothesis that Roux-en-Y
gastric bypass (RYGB) reduces circulating levels of pro-inflammatory cytokines, while increasing anti-inflammatory
cytokines in obese subjects with type 2 diabetes (T2D) and in obese normal glucose tolerant (NGT) subjects.
Methods: Thirteen obese subjects with T2D [weight; 129 ± 14 kg, glycated hemoglobin (HbA1c); 7.0 ± 0.9%,
body mass index (BMI); 43.2 ± 5.3 kg/m2, mean ± SD] and twelve matched obese NGT subjects [weight; 127 ± 15 kg,
HbA1c; 5.5 ± 0.4%, BMI; 41.5 ± 4.8 kg/m2, mean ± SD] were examined before, one week, three months, and one year
after surgery. Interleukin (IL)-6, leptin, adiponectin, IL-8, transforming growth factor beta (TGF-β), and the incretin
hormone glucagon-like peptide-1 (GLP-1) were measured in the fasting state and during a liquid meal. Insulin
resistance was evaluated by HOMA-IR.
Results: Weight loss did not differ between the two groups. Before surgery, HbA1c was higher and HOMA-IR
lower in T2D patients, however, converged to the values of NGT subjects one year after surgery. Circulating
cytokine concentrations did not differ between the two groups at any time point. One week after surgery, circulating
IL-6 and IL-8 were increased, while adiponectin and leptin were reduced compared with pre-surgical concentrations.
Three months after surgery, IL-8 was increased, leptin was reduced, and no change was observed for IL-6, TGF-β, and
adiponectin. One year after surgery, concentrations of IL-6, TGF-β, and leptin were significantly reduced compared to
before surgery, while adiponectin was significantly increased.
Conclusions: One year after RYGB, fasting concentrations of IL-6 and leptin were reduced, while no changes were
observed in IL-8. TGF-β was decreased and adiponectin increased in both T2D and NGT obese subjects. This
study is the first to examine IL-8 and TGF-β in obese subject after RYGB. Resolution of inflammation could
offer a potential explanation for the health improvement associated with major weight loss after bariatric surgery.
Trial registration: www.clinicaltrials.gov (NCT01579981).
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Background
Obesity is associated with chronic low-grade inflamma-
tion, which is thought to be involved in the development
of obesity-related co-morbidities, such as insulin resist-
ance, type 2 diabetes (T2D) and cardiovascular diseases
(CVD) [1].
The adipose tissue is considered the prime organ for
mediating obesity-induced inflammation by secreting high
levels of pro-inflammatory molecules including interleu-
kin (IL)-1, IL-6, and tumor necrosis factor-α (TNF-α) se-
creted by immune cells residing in the stromal vascular
fraction. This is thought to contribute to the development
of insulin resistance and deterioration of glucose homeo-
stasis [2-4]. Leptin is primarily produced by adipocytes
and plasma levels are elevated in obese subjects [5]. Leptin
is a central mediator in regulating food intake and energy
expenditure [6] and has been shown to inhibit insulin se-
cretion from pancreatic beta cells [7]. In addition, studies
have indicated an immunological role for leptin by indu-
cing production of IL-6 and other acute-phase reactants
[8,9]. Adiponectin is also produced predominantly by adi-
pocytes, and plasma levels of adiponectin are inversely
correlated with the body mass index (BMI) [10,11]. De-
creased levels of adiponectin have been linked to impaired
insulin sensitivity and increased risk of CVD [12,13]. The
chemokine IL-8 has been found to be produced and re-
leased from human adipocytes [14], in addition to playing
a central role in inflammation, including atherosclerotic
processes as a neutrophil chemoattractant [15,16]. Circu-
lating levels of IL-8 are increased in obesity [17,18],
in type 1 diabetes (T1D) and T2D patients compared to
lean healthy subjects [19] and compared to obese normal
glucose tolerance (NGT) subjects [20,21]. Transforming
growth factor beta (TGF-β), an immunoregulatory cyto-
kine, has also been found to be associated with obesity
and T2D [22-25].
Alterations in cytokine concentrations in NGT sub-
jects and in subjects with impaired fasting glucose, im-
paired glucose tolerance, and T2D, respectively, have
been investigated by Tönjes and co-workers [26]. In sup-
port of adipose tissue dysfunction as an early pathogenic
event in the development of T2D, the authors reported
that pre-diabetic states including impaired fasting glucose
and impaired glucose tolerance are associated with in-
creased concentrations of a range of inflammatory cyto-
kines secreted from the adipose tissue, such as chemerin,
fetuin-A and retinol binding protein 4 (RBP4) and a de-
crease in adiponectin, compared to NGT subjects. Com-
paring an obese group of NGT subjects to an obese T2D
group, the same authors found increases in chemerin,
fetuin-A, RBP4, leptin and IL-6, as well as a decrease in
adiponectin in the latter group, supporting an association
between insulin resistance and increased concentration of
circulating inflammation-related parameters [26].
Several studies in obese subjects have reported dietary-
induced weight loss to improve insulin sensitivity, in-
crease adiponectin levels and reduce circulating levels
of leptin, IL-8, and IL-6 [27-30]. Bariatric surgery, includ-
ing Roux-en-Y gastric bypass (RYGB), restores hepatic and
peripheral insulin sensitivity and often causes remission of
T2D in most cases before any substantial weight loss is
achieved [31,32]. There is a marked increase in hepatic
insulin sensitivity within one week post-surgery, while
peripheral insulin sensitivity is only improved months post-
surgery after weight loss [33]. Several studies have shown
that bariatric surgery decreases fasting plasma leptin
[34-39] and IL-6 [40-43], while increasing levels of adipo-
nectin independently of weight reduction [36,44].
Whether a more favorable inflammatory profile is linked
to the immediate improvement of insulin resistance and
resolution of T2D after RYGB is not known. In the
present study, we explore the hypothesis that the RYGB-
induced improvement in insulin resistance is associated
with decreasing pro-inflammatory and increasing anti-
inflammatory circulating cytokine levels. We examined
short- (one week and three months) and 1-year changes of
IL-6, leptin, adiponectin, IL-8, and TGF-β before and after
RYGB surgery in obese patients with T2D and in obese
NGT subjects. We hypothesized that the fasting levels of
pro-inflammatory cytokines would be higher in the T2D
group before surgery compared to the NGT group, and
that the levels in both groups would decrease and equalize
after surgery leading to a more anti-inflammatory profile
in both groups.
Recent work in rodents has shown that glucagon-like
peptide-1 (GLP-1) can be induced by a variety of inflam-
matory stimuli, including endotoxin, IL-1, and IL-6, and
in a human study, circulating GLP-1 concentrations were
increased under inflammatory conditions and correlated
with inflammatory markers including IL-6 [45,46]. Since
postprandial GLP-1 secretion is increased in RYGB-
operated patients [38,47], we studied levels of inflam-
matory markers in relation to GLP-1 responses both in
the fasting and in the postprandial period.
Methods
Study population
Study population and study design have been described
before [47]. Briefly, thirteen obese subjects with T2D
and twelve matched obese NGT subjects were recruited
from the Hvidovre Hospital bariatric surgery program
(Hvidovre, Denmark). They all met the Danish criteria
for bariatric surgery (age > 20 years and BMI > 40 kg/m2
or > 35 kg/m2 with comorbid conditions such as T2D or
hypertension), and had accomplished a mandatory pre-
operative 8% diet-induced total body weight loss before
inclusion. Patients were excluded if they had been re-
ceiving incretin-based therapies or insulin, anti-thyroid
Lindegaard et al. Diabetology & Metabolic Syndrome  (2015) 7:12 Page 2 of 12
medication or anorectic agents within three months prior
to the study.
Study design and experimental protocol
Participants were examined before and at one week,
three months, and one year postoperatively. Antidiabetic
medication was paused in diabetic subjects 72 h prior to
the preoperative meal test. After surgery, none of the
T2D subjects received any antidiabetic medication.
On each study day after a 12-h fast, participants were
weighed (Tanita, Tokyo, Japan) and then subjected to
a liquid meal test consisting of 200 ml of Fresubin
Energy Drink [300 kcal, carbohydrate (E% 50), protein
(E% 15), fat (E% 35), Fresenius Kabi Deutschland, Bad
Homburg, Germany]. The meal was ingested over a 30-min
period before and at all study visits after RYGB to avoid
dumping. Blood was sampled from a catheter in an ante-
cubital vein at −10, −5, 0, +15, +30, +45, +60, +90, +120, +180,
and +240 min compared to the start of the meal. In the
present study, only samples collected at time 0, 45, 60,
120 and 240 min were analyzed, and sample at time 0 min
was used as fasting baseline level.
Surgical procedure
Surgery was performed at the Department of Gastroenterology
at Hvidovre Hospital (Hvidovre, Denmark) as previously
described [39].
Sample collection and laboratory analysis
Blood samples were collected in clot activator tubes or
EDTA tubes. Determination of plasma insulin, GLP-1 and
glucose was carried out as described in [47]. HbA1c was
determined using HPLC (Tosoh Bioscience, Tokyo, Japan).
For protein analyses, venous blood was sampled into
EDTA tubes and kept on ice until centrifuged at 4°C,
10 min, 2000 g. Plasma aliquots were stored at −80°C
until analyzed. Total plasma concentrations of inflamma-
tory markers were determined by electrochemilumi-
nescent sandwich immunoassays (Meso Scale Discovery
(MSD), Gaithersburg, MD, USA) enabling simultaneous
quantification of multiple analytes. The assays were per-
formed according to the manufacturer’s protocol using an
MSD instrument (SECTOR Imager 2400, MSD). All sam-
ples for each individual subject were run on the same
assay plate and the same batch of kits was applied for all
samples. Samples with values greater than the upper limit
of quantification were diluted and reanalyzed. In the fast-
ing state IL-6, leptin, adiponectin, IL-8, and TGF-β were
measured, and in the postprandial samples IL-6, leptin,
adiponectin were measured.
Statistical analyses
Insulin resistance was calculated using the homeostasis
model assessment of insulin resistance (HOMA-IR) as
Insulinfasting × Glucosefasting/(22.5 × 6.945). To assess the
possible effect of RYGB on the postprandial cytokine
response, total AUC for IL-6, adiponectin, and leptin
were calculated by using the trapezoidal method
(GraphPad Prism v. 4). Statistical analyses were carried
out using Mann–Whitney U-test for comparisons
between groups. For comparisons of pre- and post-
surgical time-points, Friedman’s nonparametric repeated
measures ANOVA with Dunn’s multiple comparison
post-hoc test was applied and included only patients
with complete data set (blood sample drawn at all four
study time-points). Relationship between variables was
assessed by non-parametric Spearman rank correlation.
Statistical analysis was performed using GraphPad
Prism v. 4 (San Diego, CA, USA). The level of significance
was set at P < 0.05.
Ethics statement
Written informed consent was obtained from all partici-
pants. The study was approved by the Municipal Ethical
Committee of Copenhagen (Reg. nr. H-A-2008-080-31742)
and was in accordance with the Helsinki-II declaration
and the Danish Data Protection Agency. The study was
registered at www.clinicaltrials.gov (NCT01579981).
Results
Study population
Overview of enrolled patients is depicted in Figure 1. A
total number of 30 patients were included in the study
of which two were not operated and three subjects did
not wish to participate following surgery. One subject
with T2D could not be studied one week after RYGB be-
cause of anemia. One NGT subject was excluded from
the three-month follow-up data set, due to excessively
high fasting insulin and C-peptide concentrations, indi-
cating a non-fasting state. One NGT subject was not exam-
ined at the one-year follow-up due to pregnancy (Figure 1).
Before surgery, twelve subjects with T2D were treated
with ≥ 1 oral antidiabetic medication, and one subject was
diet-treated only. After RYGB, none of the T2D patients
received any anti-diabetic medication.
Changes in weight and glucose metabolism
Data are presented in Table 1. The most important find-
ings were that RYGB-induced weight loss in T2D subjects:
one week: 2.1% ± 1.6%, three months: 13.2% ± 3.7%, one
year: 22.2% ± 8.8% and in NGT subjects: one week: 2.5% ±
1.3%, three months: 15% ± 4.5%, and one year: 25.2% ±
8.0%. Body weight and BMI did not differ between the
two groups before or after surgery. Changes in fasting glu-
cose and insulin concentrations after surgery are given in
Table 1. Before surgery, HbA1c levels were lower in NGT
subjects compared to T2D subjects (P = 0.0002), but three
months and one year after surgery, HbA1c levels did not
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differ significantly between the groups (three months: P =
0.06, one year: P = 0.24) and HbA1c values were signifi-
cantly reduced in T2D subjects at the one-year follow-up
(P = 0.0007), while no changes occurred in NGT subjects.
HOMA-IR was lower in the NGT group before surgery
(P = 0.002), and one week (P = 0.001), and three months
(P = 0.05) after surgery compared to the T2D group, but
the levels did not differ between the two groups at the
one-year follow-up.
Fasting concentrations of inflammatory cytokines and
GLP-1
Data are presented in Figure 2. Considering the whole
study population, fasting circulating IL-6 and IL-8 levels
were increased one week after surgery, but only IL-8
reached statistical significance. At the same time point,
adiponectin and leptin levels were reduced compared
with pre-surgical concentrations. TGF-β levels did not
differ before and one week after surgery. At the three-
month follow-up, IL-8 was increased, leptin was reduced,
and no changes occurred in IL-6, TGF-β, and adiponectin
compared to before surgery. One year after surgery, how-
ever, concentrations of IL-6, TGF-β and leptin were
significantly reduced compared to before surgery, while
adiponectin was increased. IL-8 did not differ from before
and one year after surgery. We did not find any signifi-
cant differences in cytokine concentrations between the
two groups at any of the four study time-points (data not
shown).
Table 2 illustrates relevant correlations between cyto-
kine and clinical measures performed on 1-year changes
for the whole study population and in the two groups sep-
arately. The decrease in IL-6 and TGF-β correlated with
improved HbA1c in the T2D group. The increase in adi-
ponectin concentrations correlated with the decrease in
leptin. Leptin changes were positively associated with BMI
and HOMA-IR only in the NGT group. Changes in adipo-
nectin and IL-8 correlated positively with GLP-1 in the
NGT group (Table 2).
Postprandial concentrations of inflammatory cytokines
and GLP-1
The postprandial responses of cytokines and GLP-1 are
presented in Figure 3a-d and depicted as total AUC in
Table 3. Total AUC for the different cytokines in T2D
patients and NGT subjects did not differ significantly
at any study time-point and the two groups will be ana-
lyzed as one group. An increase in total AUC for IL-6
was observed one week after surgery followed by a de-
crease to preoperative response levels after three months
and after one year (Figure 3a). Total AUC for adiponec-
tin was significantly increased one year after surgery com-
pared with both before, one week, and three months after
surgery (P < 0.0001) (Figure 3b). At all post-operative
follow-ups, a significant reduction in leptin was ob-
served with no significant differences between the re-
sponses after surgery (Figure 3c) (P < 0.0001). Postprandial
GLP-1 responses were markedly increased at all three
Figure 1 Trial profile. Numbers of subjects initially enrolled are depicted and subject disposition (number of T2D vs NGT subjects, subjects who
were excluded or withdrawn, and subjects who were lost to follow up) is described.
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post-surgical follow-ups (Figure 3d) (P < 0.0001). Correl-
ation analysis revealed no associations between the post-
prandial GLP-1 response and postprandial inflammatory
cytokine responses before or after RYGB surgery (data not
shown).
Discussion
In the present study, we have assessed fasting and post-
prandial responses of IL-6, IL-8, TGF-β, leptin, and adi-
ponectin before as well as one week, three months, and
one year after RYGB in 13 obese patients with T2D and
in 12 matched obese NGT subjects. Our main findings
were that RYGB induces changes in circulating concentra-
tions of cytokines in both obese T2D patients and in obese
NGT subjects by decreasing fasting plasma concentrations
of the pro-inflammatory cytokine IL-6, leptin, and the
regulatory cytokine TGF-β, and by increasing the anti-
inflammatory adiponectin. We found an increase in IL-8
concentrations at one week and at three months after
RYGB, but one year after surgery the concentrations had
returned to preoperative levels.
Previous RYGB studies have focused primarily on well-
characterized pro-inflammatory markers and have rarely
prospectively examined acute and up to 1-year changes
after surgery of both pro- and anti-inflammatory markers.
The present study is the first to examine the pro-
inflammatory cytokine IL-8 and the regulatory cyto-
kine TGF-β after RYGB. To our knowledge, only one
other study has investigated the postprandial response of
cytokines following bariatric surgery [48].
Fasting cytokine response
We hypothesized that T2D subjects would have a higher
inflammatory burden as reflected in a more inflamma-
tory circulatory cytokine profile. We observed that pre-
surgical IL-6 concentrations in the T2D group were higher
compared to NGT subjects, although not significantly so,
which also has been shown in other studies [40,49]. Sig-
nificantly higher IL-6 concentrations have been found in
Table 1 Characteristics of type 2 diabetic subjects and normal glucose tolerant subjects
Pre-RYGB 1 week 3 months 1 year *P value
Weight (kg) N (T2D; NGT) 13; 12 12; 12 13; 11 13; 11
T2D 129 ± 14 127 ± 13 112 ± 15*** 101 ± 20*** <0.0001
NGT 127 ± 15 124 ± 15 106 ± 13** 95 ± 16*** <0.0001
†P value 0.57 0.29 0.25 0.49
BMI (kg/m2) N (T2D; NGT) 13; 12 12; 12 13; 11 13; 11
T2D 43.2 ± 5.3 42.5 ± 5.5 37.2 ± 5.8*** 34.8 ± 7.9*** <0.0001
NGT 41.5 ± 4.8 40.5 ± 4.5 34.4 ± 3.4** 31.3 ± 4.8*** <0.0001
†P value 0.34 0.4 0.12 0.42
Glucose (mmol/L) N (T2D; NGT) 13; 12 12; 12 13; 11 13; 11
T2D 8.9 ± 2.3 7.0 ± 1.1* 6.9 ± 1.6** 6.3 ± 1.6*** 0.0001
NGT 5.5 ± 0.7††† 5.0 ± 0.6††† 4.9 ± 0.4**††† 5.0 ± 0.3†† 0.01
†P value <0.0001 0.0002 0.001 0.007
HbA1c (%) N (T2D; NGT) 13; 12 13; 11 13; 10
T2D 7.0 ± 0.9 5.9 ± 0.8 5.6 ± 0.6*** 0.0007
NGT 5.5 ± 0.4††† 5.4 ± 0.3 5.4 ± 0.3 0.22
†P value 0.0002 0.06 0.24
Insulin (mmol/L) N (T2D; NGT) 13; 12 12; 12 13; 11 13; 11
T2D 125.0 ± 77.0 72.9 ± 32.1* 58.1 ± 35.4*** 46.7 ± 27.1*** <0.0001
NGT 82.2 ± 28.3 49.4 ± 13.5 42.8 ± 13.8** 35.8 ± 16.5*** 0.0001
†P value 0.29 0.053 0.6 0.45
HOMA-IR N (T2D; NGT) 13; 12 12; 12 13; 11 13; 11
T2D 6.6 ± 3.6 3.2 ± 1.5* 2.5 ± 1.7** 1.8 ± 1.1*** <0.0001
NGT 2.9 ± 1.1†† 1.6 ± 0.5†† 1.3 ± 0.5*† 1.1 ± 0.5*** 0.0002
†P value 0.002 0.001 0.047 0.11
Characteristics of T2D subjects and NGT subjects before (Pre-RYGB), 1 week, 3 months, and 1 year after Roux-en-Y gastric bypass. Data are presented as mean ±
SD. BMI, body mass index; HbA1c, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; NGT, normal glucose tolerance; T2D, type
2 diabetes. *P-value for overall comparison of time-points within groups, *P < 0.05, **P < 0.01, ***P < 0.0001; †P-value for comparison between groups, †P < 0.05,
††P < 0.01, †††P < 0.0001.
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T2D subjects when compared to healthy obese subjects
[50], which, in relation to the decrease in IL-6 we observe
one year after RYGB associated with improvement of glu-
cose metabolism, may imply a role of IL-6 in glycemic
control when insulin resistance is present. However, a
clear conclusion about causality cannot be obtained from
the present study and the role of IL-6 in T2D and in insu-
lin resistance remains debatable [51].
Despite earlier findings that impaired insulin sensitiv-
ity is associated with changes in a range of inflammatory
markers including RBP4, IL-6, leptin, and adiponectin
[26] we were unable to show differences in fasting con-
centrations of cytokines between T2D patients and NGT
subjects at any study time-point. This may in part be ex-
plained by the mandatory preoperative 8% diet-induced
total weight loss before surgery and that both groups
displayed morbid obesity with a mean BMI of about
42 kg/m2. Nevertheless, insulin resistance evaluated by
HOMA-IR was more pronounced in T2D patients be-
fore and the first three months after surgery. One year
after RYGB, insulin resistance did not differ between the
two experimental groups. The present study was, how-
ever, not designed to investigate the relative role of the
inflammatory parameters in relation to insulin resist-
ance, insulin secretion, and development of T2D.
The reductions in IL-6 concentrations we report one
year after RYGB is in agreement with some other RYGB
studies [41,42] and consistent with other weight loss
intervention studies reporting 1-year follow-ups, either
through dietary restriction [30] or other types of bariat-
ric surgery procedures [40,43,49]. Other studies have re-
ported decrease in IL-6 within six months after surgery
[52], while other investigators have not been able to de-
tect any changes [34,36,53,54].
The increase in fasting concentrations of the anti-
inflammatory adiponectin is consistent with the findings
of a number of RYGB studies [34,36,44]. Brethauer and
co-workers found an increase in adiponectin appearing
three months after surgery [34], while Trakhtenbroit and
co-workers report lack of increase until two years after
RYGB with no changes observed in a cohort of T2D sub-
jects undergoing gastric banding. Subjects in the RYGB
group lost significantly more fat mass than the gastric
banding group [55].
The decrease in adiponectin we observe immediately
after surgery, has, to our knowledge, not been reported
Figure 2 a-f Fasting plasma concentrations of inflammatory cytokines and GLP. Fasting plasma concentrations of (a) IL-6 (N = 18), (b) IL-8
(N = 18), (c) TGF-β (N = 22), (d) adiponectin (N = 20), (e) leptin (N = 18), and (f) GLP-1 (N = 21) before (Pre-RYGB), one week, three months, and one
year after Roux-en-Y gastric bypass in the whole study population. Data are presented as mean ± SEM. Only patients with complete fasting data
set (samples drawn at all four time points) were included. Comparisons between time-points was made using ANOVA (non-parametric Friedman
test for repeated measures) followed by Dunn’s multiple test for statistical differences, *P < 0.05, **P < 0.01, ***P < 0.001.
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Table 2 Correlation coefficients of 1-year changes
Variable 1 Variable 2 Whole group r(N; P) NGT group r(N; P) T2D group r(N; P)
IL-6 BMI 0.16(20; 0.49) 0.01(9; 0.98) 0.28(11; 0.40)
HOMA-IR 0.19(20; 0.19) −0.07(9; 0.88) 0.21(11; 0.52)
HbA1c 0.47(19; 0.04) 0.02(8; 0.98) 0.82(11; 0.002)
TGF-β 0.65(20; 0.002) 0.70(9; 0.04) 0.71(11; 0.01)
IL-8 BMI 0.02(20; 0.92) −0.13(9; 0.73) 0.03(11; 0.94)
HOMA-IR 0.06(20; 0.81) −0.20(9; 0.61) 0.37(11; 0.26)
HbA1c −0.14(19; 0.57) 0.15(8; 0.73) 0.45(11; 0.17)
GLP-1 0.59(20; 0.007) 0.80(9; 0.01) 0.54(11; 0.09)
Adiponectin 0.35(20; 0.12) 0.67(9; 0.05) 0.27(11; 0.42)
TGF-β BMI 0.28(24; 0.19) 0.37(11; 0.26) 0.25(13; 0.42)
HOMA-IR 0.05(24; 0.81) −0.10(11; 0.77) 0.19(13; 0.54)
HbA1c 0.25(23; 0.26) 0.07(10; 0.84) 0.64(13; 0.02)
Adiponectin BMI −0.40(21; 0.07) −0.28(9; 0.11) −0.42(12; 0.17)
HOMA-IR −0.28(21; 0.21) −0.57(9; 0.11) −0.19(12; 0.56)
HbA1c −0.06(20; 0.79) −0.07(8; 0.86) −0.32(12; 0.31)
GLP-1 0.47(21; 0.03) 0.87(9; 0.003) 0.16(12; 0.62)
Leptin −0.58(21; 0.01) −0.68(9; 0.04) −0.36(12; 0.26)
Leptin BMI 0.65(21; 0.002) 0.75(9; 0.02) 0.56(12; 0.06)
HOMA-IR 0.36(21; 0.11) 0.72(9; 0.03) 0.45(12; 0.14)
HbA1c −0.14(20; 0.55) 0.41(8; 0.31) −0.08(12; 0.19)
Insulin 0.51(21; 0.02) 0.28(9; 0.46) 0.41(12; 0.81)
Clinically relevant significant and non-significant correlation coefficients in the whole study population and in T2D subjects and NGT subjects. Data are presented
as r: correlation coefficient of correlation, and the sample size and P-value in parentheses. NGT, normal glucose tolerant subjects; T2D, type 2 diabetes subjects;
BMI, body mass index; HbA1c, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance. Data are analyzed by Spearman correlation
test, P < 0.05.
Figure 3 Postprandial cytokine and GLP-1 response in the whole study population. Postprandial response of (a) IL-6, (b) adiponectin,
(c) leptin, and (d) GLP-1 in the whole study population before (Pre-RYGB) (N = 21), one week (N = 20), three months (N = 20), and one
year (N = 20) after Roux-en-Y gastric bypass in the whole study population. Data are presented as mean ± SEM.
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before. In a study with obese subjects undergoing lipo-
suction, decreases in adiponectin in addition to increases
in IL-6 was reported and was suggested to indicate that
IL-6 suppresses adiponectin secretion [56]. In vivo stud-
ies in obese subjects have shown that low levels of
plasma adiponectin were inversely correlated with circu-
lating IL-6 [28,57]. While in vitro studies have demon-
strated downregulation of adiponectin mRNA in adipose
tissue fragments incubated with IL-6 [28,58], adiponec-
tin has also been shown to increase insulin sensitivity
through an IL-6-dependent pathway [59]. We did, how-
ever, not observe any correlation between changes in
adiponectin concentrations and in IL-6, IL-8, or TGF-β
levels or in HOMA-IR. Thus, our results do not support
a role for adiponectin as mediator of the improved insu-
lin sensitivity early after surgery.
The changes in adiponectin were negatively associated
with leptin in the NGT group only. There is a well-reported
inverse relationship between adiponectin and leptin as
they are both secreted and regulated by the adipose tissue,
so we would have expected this correlation to be present
in both groups.
We found a reduction in circulating leptin as early as
one week after surgery and before significant changes in
body weight; a finding which is supported by Isbell and
co-workers and others with two- and three-week post-
surgical follow-ups [35,37,39,60,61]. Reduction of circulat-
ing leptin during caloric restriction has been suggested to
be an essential component of the neuroendocrine re-
sponse to fasting [62,63], and the immediate decrease in
leptin could therefore potentially be ascribed to post-
surgical caloric restriction rather than the RYGB proced-
ure itself. The decrease in leptin concentrations one year
after surgery was associated with improved BMI measures
and HOMA-IR in the NGT group only.
Lack of effect on inflammation-related circulating cyto-
kines after RYGB could be explained by the short duration
of some studies, and may suggest that either a certain
amount of weight loss, a period of weight stabilization or
improvement of metabolic instability is required before
changes in plasma concentrations are manifested. The
maximal weight loss after RYGB is obtained between
1–1.5 year after surgery [64], and evidence seems to sug-
gest that at least two years is required post-surgery for
stabilization of the inflammatory profile [65]. In addition,
the surgical procedure and subsequent healing process
might elicit an inflammatory response delaying the
weight-induced reduction in inflammatory cytokines
Table 3 Total AUC for IL-6, adiponectin, leptin and GLP-1 in response to meal intake
Total AUC Mean (95% CI) P-value
IL-6 (pg/ml × 240 min) N = 18 0.001
Pre-RYGB 1525 (1151; 1899)
1 week 3897 (530; 7264)
3 months 1471 (1099; 1843)
1 year 1312 (803; 1821)b
Adiponectin (μg/ml × 240 min) N = 18 <0.0001
Pre-RYGB 2006 (1615; 2398)
1 week 1891 (1505; 2278)
3 months 2188 (1801; 2575)b
1 year 3541 (2821; 4261)a,b,c
Leptin (ng/ml × 240 min) N = 18 <0.0001
Pre-RYGB 16997 (11138; 22856)
1 week 8883 (5600; 12166)a
3 months 9113 (4981; 13245)a
1 year 7883 (3904; 11862)a
GLP-1 (pmol/l × 240 min) N = 21 <0.0001
Pre-RYGB 2742 (2433; 3051)
1 week 10257 (7962; 12551)a
3 months 11606 (8833; 14379)a
1 year 11642 (8398; 14886)a
Total AUC for IL-6 (N = 18), adiponectin (N = 18), leptin (N = 18), and GLP-1 (N = 21) in response to meal intake measured in the whole study population before
(Pre-RYGB), 1 week, 3 months, and 1 year after Roux-en-Y gastric bypass. Data are presented as mean with 95% confidence interval (CI). Comparisons between
time-points was made using ANOVA (non-parametric Friedman test for repeated measures) followed by Dunn’s multiple test for statistical differences, adifferent
from pre-surgical levels, bdifferent form one-week level, and cdifferent from one year level, P < 0.05.
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until several months after surgery. Another explanation
for a delay in reduction of pro-inflammatory mediators
may be that the restrictive diet following surgery resem-
bles a state of starvation, which has been shown to initiate
certain pro-inflammatory responses [66].
To our knowledge, the response of the pro-inflammatory
cytokine IL-8 and the regulatory TGF-β has not previously
been studied in relation to bariatric surgery. The observed
increase in IL-8 after RYGB is of interest as this chemokine
potentially is involved in the pathogenesis of atheroscler-
osis and CVD [16], and thus, we would have expected that
a health promoting intervention like RYGB should result
in a lowering of IL-8 levels. Similar to our finding, Bruun
and coworkers reported an increase in IL-8 after 20 weeks
and 24 weeks, respectively, of dietary-induced weight loss
of approximately 15% [17,27]. Other cell types besides adi-
pocytes involved in acute and chronic inflammatory re-
sponses could add to the secretion of IL-8 [67] and this
could evidently also be the case after acute weight loss. In
addition, other substances released from the adipose tissue
during weight loss, such as organochlorine compounds,
may also stimulate the release of IL-8 [68] and of other adi-
pose tissue-derived cytokines [69]. The immediate increase
after RYGB could also be a surgery-related stress response,
as recently suggested [70].
Studies measuring circulating TGF-β are somewhat
limited due to TGF-β being present in an inactive form
requiring proteolytic activation. Furthermore, TGF-β is
released during the coagulation process complicating
comparisons between measurements obtained in serum
versus plasma [71]. These analytic difficulties might ex-
plain to some degree the diverging conclusions on TGF-β
in diabetes research. Our data on TGF-β suggest ele-
vated levels in the obese state as the RYGB-induced
weight loss induced a decrease in circulatory TGF-β con-
centrations. Herder and co-workers found that enhanced
levels of TGF-β were linked to increased risk of T2D [24].
The relevance of a reduction in TGF-β is, however, diffi-
cult to evaluate as the influence of weight loss on TGF-β
concentrations and the metabolic impact of either in-
creasing or decreasing these concentrations in humans
is unknown.
Postprandial cytokine response
The prandial levels of cytokines followed the changes in
fasting plasma levels, and consistent with previous work
in obese and/or diabetic subjects no postprandial changes
in leptin or adiponectin concentrations were observed
[29,72-74]. A small transient decrease in IL-6 concentra-
tions was observed immediately after food intake followed
by an increase lasting for the remainder of the meal test
reaching final concentrations above baseline. The initial
decrease and the following increase in postprandial IL-6
concentrations in obese and/or T2D have been demon-
strated before [53,75-79].
IL-6 has been reported to have an effect on the secre-
tion of GLP-1 by intestinal L-cells [45], and circulating
levels of GLP-1 has been found to correlate with systemic
IL-6 concentrations and other markers of inflammation
suggesting an inflammation-dependent regulation of GLP-1
secretion [46]. These finding might indicate a cross-talk
between the gut and the immune system. In the present
study, we found changes in fasting GLP-1 to be positively
associated with IL-8 and with adiponectin, whereas no as-
sociation between postprandial GLP-1 secretion and IL-6
or other cytokine responses could be demonstrated.
The present study has several limitations; participants
were included after a preoperative weight loss of about
8%, likely to improve several metabolic parameters, espe-
cially hepatic insulin sensitivity, but could also have affected
the inflammatory profile in the two groups. Nevertheless,
postoperative metabolic improvements were still observed,
although the magnitude probably had been greater if par-
ticipants had not been subjected to the preoperative
weight loss. The study was based on the assumption that a
postprandial response would be a more sensitive measure
of endocrine changes and therefore the study was pow-
ered to take advantage of this, meaning that small postop-
erative changes in fasting circulatory levels may not reach
statistically significance. In the present study, inclusion of
more patients could have increased the power of the stat-
istical analysis and strengthened the study. Here we use
HOMA-IR which has been shown to correlate well with
full body insulin sensitivity [80]. However, in states of cal-
oric restriction, HOMA-IR probably reflects hepatic insu-
lin sensitivity more than whole body insulin sensitivity
[81], which makes it difficult to evaluate the relationship
between changes in inflammatory markers and changes in
hepatic and peripheral muscle and fat tissue insulin sensi-
tivity. Finally, we did not include a control group sub-
jected to the same postoperative diet, which would be of
major interest provided that diet-adherence can be con-
trolled. Therefore, as other bariatric surgery studies, the
present study lacks a clinically relevant control group
representing a comparable non-operative-induced weight
loss.
Conclusion
Low-grade chronic inflammation associated with obesity
is considered a major risk factor for the development of
obesity-related comorbidities, such as insulin resistance and
CVD. Resolution of the unfavorable inflammatory state
could offer a potential explanation for the health improve-
ment associated with major weight loss after bariatric
surgery. In the present study, short and up to 1-year
changes in cytokines and metabolic variables were re-
ported in obese patients with T2D and in obese NGT
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subjects after RYGB surgery. Pre-operative levels of
inflammatory mediators did not differ between the two
groups. RYGB reduced fasting and postprandial concen-
trations of the pro-inflammatory cytokines IL-6, leptin,
and the regulatory cytokine TGF-β to a similar extent
in both groups. The anti-inflammatory adiponectin was
increased, while the pro-inflammatory IL-8 did not differ
before and after surgery. Notably, this study is the first to
examine and report changes in IL-8 and TGF-β in obese
subject after RYGB.
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